Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Arch Immunol Ther Exp (Warsz) ; 47(6): 377-85, 1999.
Artigo em Inglês | MEDLINE | ID: mdl-10608295

RESUMO

A proline-rich polypeptide (PRP) complex, subsequently called Colostrinin, was isolated from ovine colostrum. The complex showed immunomodulatory properties in mice, rats, and chickens, inducing maturation and differentiation of thymocytes. It was recently found that Colostrinin is a cytokine-like factor that acts as an inducer of interferon gamma (IFN-gamma) and other cytokines in human peripheral blood and cord blood leukocyte cultures and has psycho-immuno-enhancing activity in volunteers. These observations prompted us to study the effect of Colostrinin on patients with Alzheimer's disease (AD). Forty six AD patients were divided into 3 groups and randomly assigned to receive orally either Colostrinin (100 microg per tablet, every second day), commercially available bioorganic selenium (100 microg selenium per tablet, every second day) or placebo tablets. One cycle of the treatment lasted 3 weeks and was separated from the next cycle by a 2 week hiatus. Each patient received 10 cycles of treatment during the year of the clinical trial. Outcomes were assessed by psychiatrists blinded to the treatment assignment. Eight of the 15 AD patients treated with Colostrinin improved and in the 7 others the disease had stabilized. In contrast, none of the 31 patients from the selenium or placebo groups with similar mild or moderate AD improved. The administration of selenium promoted stabilization in 13 of the 15 patients, whereas in the placebo group only 8 of the 16 patients were stabilized at the 12 month trials end-evaluation. Colostrinin was found to be a remarkably safe drug. Mild and transient effects were anxiety, stimulation, insomnia, and tiredness. The results obtained showed that oral administration of Colostrinin improves the outcome of AD patients with mild to moderate dementia. The results are very encouraging and deserve further research.


Assuntos
Adjuvantes Imunológicos/uso terapêutico , Doença de Alzheimer/tratamento farmacológico , Colostro/química , Peptídeos/uso terapêutico , Adjuvantes Imunológicos/efeitos adversos , Adjuvantes Imunológicos/isolamento & purificação , Doença de Alzheimer/psicologia , Animais , Disponibilidade Biológica , Galinhas , Método Duplo-Cego , Feminino , Humanos , Camundongos , Peptídeos/efeitos adversos , Peptídeos/isolamento & purificação , Gravidez , Domínios Proteicos Ricos em Prolina , Ratos , Segurança , Selênio/uso terapêutico , Ovinos
2.
Rocz Akad Med Bialymst ; 44: 35-46, 1999.
Artigo em Inglês | MEDLINE | ID: mdl-10697418

RESUMO

This study presents the actual lichen flora of Suprasl. 68 species have been collected in the investigated area. Among these, 53 are epiphytic species, 12 are epilithic species and 17--epiksylithic species. On the basis of lichens scale, Suprasl was classified to 6th bioindicative zone, where air pollution of SO2 was 30-40 mg/m3.


Assuntos
Líquens , Estâncias para Tratamento de Saúde , Humanos , Polônia
3.
Postepy Hig Med Dosw ; 52(3): 207-22, 1998.
Artigo em Polonês | MEDLINE | ID: mdl-9789432

RESUMO

Selenium deficiency occurs in many regions of the world including Poland. It leads to human body dysfunctions and diseases among which Keshan disease is the most known. Biologically active selenium is usually incorporated into proteins as selenocysteine, which is the most useful in nutritional supplementation. Selenium addition is important since many viruses are more pathogenic when deficiency of this element occurs.


Assuntos
Selênio/deficiência , Selênio/metabolismo , Suplementos Nutricionais , Humanos , Vírus/metabolismo , Vírus/patogenicidade
4.
Otolaryngol Pol ; 51 Suppl 25: 285-9, 1997.
Artigo em Polonês | MEDLINE | ID: mdl-9757712

RESUMO

At 25 patients with Bell's palsy every 7 days stapedius reflex (SR), accommodation coefficient as well as improvement of mimical facial movements were examined. At 5 patients SR was noticed before treatment, at 13 after 14 days, at 4 after 21 and at 3 after 28 days since disease beginning. There was significant correlation between return SR and improvement of mimical facial movements, but there wasn't correlation between SR and accommodation coefficient.


Assuntos
Nervo Facial/fisiopatologia , Paralisia Facial/fisiopatologia , Estapédio/fisiologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Progressão da Doença , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Prognóstico , Reflexo/fisiologia , Fatores de Tempo
5.
Arch Immunol Ther Exp (Warsz) ; 45(1): 109-17, 1997.
Artigo em Inglês | MEDLINE | ID: mdl-9090449

RESUMO

We have tentatively identified colostrinines as novel cytokines produced by the mammary gland after delivery and detectable in colostrum. The primary colostrinine, the proline-rich polypeptide, was isolated from ovine colostrum in 1974. It is generally understood that the various factors present in colostrum play a pivotal role in transmitting of passive or active immunity from mother to child. We have found previously that both ovine and human colostrinines are inducers of interferon (IFN) gamma and other cytokines. In this paper, we reported that the leukocytes isolated from human colostrum donated by healthy mothers at 1-9 days after delivery, produced IFNs and tumor necrosis factors (TFNs) spontaneously. The release of IFNs and TNFs coincided with production of a colostrinine that has been isolated from the human colostrum samples and partially characterized. Our results suggest that the maximum production of colostrinine occurs 3 days after delivery. The tolerance (hyporeactivity) of the colostral leukocytes to IFN inducers and the modulation of the TNF response may be the late effects of the colostrinine release.


Assuntos
Mama/metabolismo , Colostro/metabolismo , Interferons/metabolismo , Leucócitos/metabolismo , Biossíntese Peptídica , Período Pós-Parto/imunologia , Fator de Necrose Tumoral alfa/metabolismo , Mama/citologia , Colostro/citologia , Feminino , Humanos , Tolerância Imunológica/efeitos dos fármacos , Peptídeos e Proteínas de Sinalização Intercelular , Indutores de Interferon/imunologia , Interferons/biossíntese , Peptídeos/isolamento & purificação , Período Pós-Parto/metabolismo , Fatores de Tempo , Fator de Necrose Tumoral alfa/biossíntese
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...